Citations

Citations to this article as recorded by  

• Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants
  Yue Xi, Rongrong Ma, Shuo Li, Gang Liu, Chao Liu
  Vaccines.2024; 12(7): 764.     CrossRef
• Biomimetic virus-like particles with magnetic core. From bioactivity to an immunodiagnostic tool
  Adam A. Mieloch, Anna M. Mleczko, Anna Samelak-Czajka, Paulina Jackowiak, Jakub D. Rybka
  Chemical Engineering Journal.2024; 485: 149714.     CrossRef
• The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2
  Yuan Hu, Lili Liu, Shenghua Zhang, Shaoyu Su, Xiao Liang
  ACS Omega.2024; 9(5): 5175.     CrossRef
• Construction and immunogenicity of SARS-CoV-2 virus-like particle expressed by recombinant baculovirus BacMam
  Hai Trong Nguyen, Darryl Falzarano, Volker Gerdts, Qiang Liu, Leonidas Stamatatos
  Microbiology Spectrum.2024;[Epub]     CrossRef
• Engineering Escherichia coli-Derived Nanoparticles for Vaccine Development
  Shubing Tang, Chen Zhao, Xianchao Zhu
  Vaccines.2024; 12(11): 1287.     CrossRef
• A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates
  Yuanyuan Li, Siyu Tian, Yuanbao Ai, Zhulong Hu, Chao Ma, Meijuan Fu, Zhenqian Xu, Yan Li, Shuyun Liu, Yongjuan Zou, Yu Zhou, Jing Jin
  Frontiers in Immunology.2024;[Epub]     CrossRef
• Design and Application of Biosafe Coronavirus Engineering Systems without Virulence
  Guoqiang Wu, Qiaoyu Li, Junbiao Dai, Guobin Mao, Yingxin Ma
  Viruses.2024; 16(5): 659.     CrossRef
• From Sequence to System: Enhancing IVT mRNA Vaccine Effectiveness through Cutting-Edge Technologies
  Lifeng Xu, Chao Li, Rui Liao, Qin Xiao, Xiaoran Wang, Zhuo Zhao, Weijun Zhang, Xiaoyan Ding, Yuxue Cao, Larry Cai, Joseph Rosenecker, Shan Guan, Jie Tang
  Molecular Pharmaceutics.2024;[Epub]     CrossRef
• Use of virus-like particles and nanoparticle-based vaccines for combating picornavirus infections
  Mei Ren, Sahibzada Waheed Abdullah, Chenchen Pei, Huichen Guo, Shiqi Sun
  Veterinary Research.2024;[Epub]     CrossRef
• Nanovaccines to combat drug resistance: the next-generation immunisation
  K. Manju, S. Niranjan Raj, H. K. Ranjini, S. Chandra Nayaka, P. Ashwini, S. Satish, M. N. Nagendra Prasad, Raghuraj Singh Chouhan, Syed Baker
  Future Journal of Pharmaceutical Sciences.2023;[Epub]     CrossRef
• Multivalent vaccines against new SARS-CoV-2 hybrid variants
  Kiarash Ghazvini, Masoud Keikha
  Vacunas.2023; 24(1): 76.     CrossRef
• Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant
  Tae-Hun Kim, Sojung Bae, Sunggeun Goo, Jinjong Myoung
  Journal of Microbiology and Biotechnology.2023; 33(12): 1587.     CrossRef
• The SeroNet Clinical and Translational Serology Task Force (CTTF) SARS-CoV-2 mucosal immunity methodological considerations and best practices workshop
  Heidi Hempel, Nicholas Mantis, Christopher D. Heaney, Ligia A. Pinto
  Human Vaccines & Immunotherapeutics.2023;[Epub]     CrossRef
• Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
  Sareh Kakavandi, Iman Zare, Maryam VaezJalali, Masoud Dadashi, Maryam Azarian, Abdullatif Akbari, Marzieh Ramezani Farani, Hamidreza Zalpoor, Bahareh Hajikhani
  Cell Communication and Signaling.2023;[Epub]     CrossRef
• Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2
  Maluta Steven Mufamadi, Mpho Phehello Ngoepe, Ofentse Nobela, Nhlanhla Maluleke, Bafedile Phorah, Banele Methula, Thapelo Maseko, Dipuo Ingrid Masebe, Hazel Tumelo Mufhandu, Lebogang Maureen Katata-Seru, Claudio Acuña-Castillo
  BioMed Research International.2023;[Epub]     CrossRef
• Current progress in the development of prophylactic and therapeutic vaccines
  Tingting Li, Ciying Qian, Ying Gu, Jun Zhang, Shaowei Li, Ningshao Xia
  Science China Life Sciences.2023; 66(4): 679.     CrossRef
• Multivalent vaccines against new SARS-CoV-2 hybrid variants
  Kiarash Ghazvini, Masoud Keikha
  Vacunas (English Edition).2023; 24(1): 76.     CrossRef
• Post‐Assembly Modification of Protein Cages by Ubc9‐Mediated Lysine Acylation
  Mikail D. Levasseur, Raphael Hofmann, Thomas G. W. Edwardson, Svenja Hehn, Manutsawee Thanaburakorn, Jeffrey W. Bode, Donald Hilvert
  ChemBioChem.2022;[Epub]     CrossRef
• An S1-Nanoparticle Vaccine Protects against SARS-CoV-2 Challenge in K18-hACE2 Mice
  Linda van Oosten, Kexin Yan, Daniel J. Rawle, Thuy T. Le, Jort J. Altenburg, Cyrielle Fougeroux, Louise Goksøyr, Willem Adriaan de Jongh, Morten A. Nielsen, Adam F. Sander, Gorben P. Pijlman, Andreas Suhrbier, Mark T. Heise
  Journal of Virology.2022;[Epub]     CrossRef
• Expression and Immunogenicity of SARS-CoV-2 Virus-Like Particles based on Recombinant Truncated HEV-3 ORF2 Capsid Protein
  Yong-Fei Zhou, Jiao-Jiao Nie, Chao Shi, Ke Ning, Yu-Feng Cao, Yanbo Xie, Hongyu Xiang, Qiuhong Xie
  Journal of Microbiology and Biotechnology.2022; 32(10): 1335.     CrossRef
• Two years of COVID-19 pandemic: where are we now?
  Jinjong Myoung
  Journal of Microbiology.2022; 60(3): 235.     CrossRef
• Immunogenicity and protective potential of chimeric virus-like particles containing SARS-CoV-2 spike and H5N1 matrix 1 proteins
  Jing Chen, Wang Xu, Letian Li, Lichao Yi, Yuhang Jiang, Pengfei Hao, Zhiqiang Xu, Wancheng Zou, Peiheng Li, Zihan Gao, Mingyao Tian, Ningyi Jin, Linzhu Ren, Chang Li
  Frontiers in Cellular and Infection Microbiology.2022;[Epub]     CrossRef
• Construction, Characterization, and Application of a Nonpathogenic Virus-like Model for SARS-CoV-2 Nucleocapsid Protein by Phage Display
  Yuting Wu, Bing Liu, Zhiwei Liu, Pengjie Zhang, Xihui Mu, Zhaoyang Tong
  Toxins.2022; 14(10): 683.     CrossRef
• Contribution of T- and B-cell intrinsic toll-like receptors to the adaptive immune response in viral infectious diseases
  Ejuan Zhang, Zhiyong Ma, Mengji Lu
  Cellular and Molecular Life Sciences.2022;[Epub]     CrossRef